Evidence map›Paper›PMID 26522728›Full record

ArticleOncogene2016

The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer.

C Rey, B Faustin, I Mahouche, R Ruggieri, C Brulard, F Ichas, I Soubeyran, L Lartigue, F De Giorgi

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

C ReyLaboratoire de Validation et Identification de Nouvelles Cibles en Oncologie (VINCO), INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France.
B FaustinCNRS - CIRID, Bordeaux Cedex, France.
I MahoucheLaboratoire de Validation et Identification de Nouvelles Cibles en Oncologie (VINCO), INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France.
R RuggieriLaboratory of Cell Signaling, The Feinstein Institute for Medical Research, Manhasset, NY, USA.
C BrulardLaboratoire de Validation et Identification de Nouvelles Cibles en Oncologie (VINCO), INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France.
F IchasFluofarma, 2 rue R. Escarpit, Pessac, France.
I SoubeyranDépartement de Biopathologie, Institut Bergonié, Bordeaux, France.
L LartigueLaboratoire de Validation et Identification de Nouvelles Cibles en Oncologie (VINCO), INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France.
F De GiorgiFluofarma, 2 rue R. Escarpit, Pessac, France.
Institut Bergonié · FRFeinstein Institute for Medical Research · USImmunology from Concept and Experiments to Translation · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Often described as a mediator of cell cycle arrest or as a pro-apoptotic factor in stressful conditions, the MAP3K ZAK (Sterile alpha motif and leucine zipper-containing kinase) has also been proven to positively regulate epidermal growth factor receptor (EGFR) and WNT signaling pathways, cancer cell proliferation and cellular neoplastic transformation. Here, we show that both isoforms of ZAK, ZAK-α and ZAK-β are key factors in cancer cell migration. While ZAK depletion reduced cell motility of HeLa and HCT116 cells, its overexpression triggered the activation of all three mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK), c-JUN N-terminal kinase (JNK) and p38, as well as an increase in cell motion. On the contrary, the kinase-dead mutants, ZAK-α K45M and ZAK-β K45M, were not able to provoke such events, and instead exerted a dominant-negative effect on MAPK activation and cell migration. Pharmacological inhibition of ZAK by nilotinib, preventing ZAK-autophosphorylation and thereby auto-activation, led to the same results. Activated by epidermal growth factor (EGF), we further showed that ZAK constitutes an essential element of the EGF/ERK-dependent cell migration pathway. Using public transcriptomic databases and tissue microarrays, we finally established that, as strong factors of the EGFR signaling pathway, ZAK-α and/or ZAK-β transcripts and protein(s) are frequently upregulated in colorectal adenoma and carcinoma patients. Notably, gene set enrichment analysis disclosed a significant correlation between ZAK+ colorectal premalignant lesions and gene sets belonging to the MAPK/ERK and motility-related signaling pathways of the reactome database, strongly suggesting that ZAK induces such pro-tumoral reaction cascades in human cancers.

Indexed as

Cell MovementCell ProliferationColorectal NeoplasmsExtracellular Signal-Regulated MAP KinasesHumansMAP Kinase Kinase KinasesMAP Kinase Signaling SystemProtein KinasesTransfectionUp-RegulationExtracellular Signal-Regulated MAP KinasesMAP3K20 protein, humanMAP Kinase Kinase KinasesProtein Kinases

Identifiers

PMID26522728
OpenAlexW2212195257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.